Department of Otorhinolaryngology-Head & Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University School of Medicine Ear Institute, Shanghai Key Laboratory of Translational Medicine On Ear and Nose Diseases, Shanghai, 200092, China.
Department of Oral Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, 200011, China.
Clin Oral Investig. 2024 Feb 9;28(2):140. doi: 10.1007/s00784-024-05531-7.
To dynamically compare the longitudinal (time axis) and transverse (between groups) differences of the salivary cytokines during thalidomide maintenance treatment of recurrent aphthous stomatitis.
A randomized, controlled, clinical trial was performed. After the initial prednisone treatment, thalidomide (50 mg/d vs. 25 mg/d) was used as a maintenance drug for 4 or 8 weeks. The salivary IL-4, 5, 6, 10, TNF-α, and IFN-γ were dynamically detected with a cytometric bead array.
Overall, the level of six elevated salivary cytokines after prednisone treatment was significantly downregulated, remained low during thalidomide maintenance, and rebounded at recurrence. The effect of 50 mg/d thalidomide on the salivary cytokines was not superior to 25 mg/d medication. The relapse-free period following drug withdrawal was the longest in the subgroup using 25 mg/d thalidomide for 8 weeks. The order of magnitude of IL-6 was the most obvious, and at week 8, only the level of IL-6 in the group (25 mg/d thalidomide for 8 weeks) continued to decline compared with the other groups.
Thalidomide maintenance treatment can effectively sustain low levels of salivary IL-4, 5, 6, 10, TNF-α, and IFN-γ of recurrent aphthous stomatitis patients. IL-6 displayed a good correlation with the disease and is expected to become an index for diagnosis and follow-up.
Low-dose long-term thalidomide maintenance treatment was supported for recurrent aphthous stomatitis.
Trial registration number of ChiCTR-IPR-16009759 at http://www.chictr.org/index.aspx .
动态比较沙利度胺维持治疗复发性阿弗他溃疡期间唾液细胞因子的纵向（时间轴）和横向（组间）差异。
进行了一项随机、对照、临床试验。在初始泼尼松治疗后，将沙利度胺（50mg/d 与 25mg/d）作为维持药物使用 4 或 8 周。使用流式细胞术微珠阵列动态检测唾液中 IL-4、5、6、10、TNF-α 和 IFN-γ。
总体而言，泼尼松治疗后六种升高的唾液细胞因子的水平显著下调，在沙利度胺维持期间保持较低水平，并在复发时反弹。50mg/d 沙利度胺对唾液细胞因子的作用并不优于 25mg/d 药物。停药后无复发期最长的是使用 25mg/d 沙利度胺 8 周的亚组。IL-6 的数量级最明显，在第 8 周，仅在该组（25mg/d 沙利度胺 8 周）中，IL-6 的水平与其他组相比继续下降。
沙利度胺维持治疗可有效维持复发性阿弗他溃疡患者唾液中 IL-4、5、6、10、TNF-α 和 IFN-γ 的低水平。IL-6 与疾病相关性好，有望成为诊断和随访的指标。
支持低剂量长期沙利度胺维持治疗复发性阿弗他溃疡。
ChiCTR-IPR-16009759 在 http://www.chictr.org/index.aspx 进行注册。
